Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arcus Biosciences, Inc.

https://www.arcusbio.com/

Latest From Arcus Biosciences, Inc.

Roche Stays Upbeat Amid Skepticism On Tiragolumab’s Chances

Analysts are keen to know more about the statistical weighting of Roche’s SKYSCRAPER 1 study of the TIGIT inhibitor, while Merck & Co can learn from their rival’s slip-up for their own trial design.

Cancer Companies

Bad Omen Or Opportunity? Roche’s TIGIT Failure Hits Rivals Hard

After two failures in a row from Roche, the TIGIT hypothesis is looking shaky, but it is too early to write off the class yet.

Companies Research & Development

2022 Will Be A Test For Gilead, Starting with TROPiCS-2 Study Of Trodelvy

Even as magrolimab stumbled, the company remains optimistic about the rest of its pipeline, from potential pipeline-in-a-pill Trodelvy to an oral COVID-19 drug.

Sales & Earnings ImmunoOncology

Gilead Aims For Oncology To Provide One-Third Of Revenues By 2030

At the J.P. Morgan meeting, the company said its business development priorities have not changed, but it plans to prioritize licensing and small acquisitions rather than big ticket deals in 2022.

ImmunoOncology Companies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register